Physician profile
Derrick Bieller
NPI 1063982734
$3,131.73
in general payments reported to CMS, 2019-2025
20 companies · $1,979 in 2025
The $1,979 reported for 2025 was more than what 93% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $641 · 2024: $513 · 2025: $1,979.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,856 · Education: $276.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,856.07 |
| Education | $275.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $383.19 | 2023-2025 | Spravato, Invega Sustenna |
| Neurocrine Biosciences, INC. | $355.65 | 2023-2025 | Ingrezza |
| Lundbeck LLC | $346.92 | 2023-2025 | Rexulti, Vyepti |
| Teva Pharmaceuticals USA, INC. | $331.84 | 2023-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Abbvie INC. | $308.99 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $270.81 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $246.44 | 2023-2025 | Caplyta |
| Alkermes, INC. | $227.34 | 2023-2025 | Aristada, Lybalvi, Aristada Initio |
| Jazz Pharmaceuticals INC. | $127.97 | 2025 | |
| Corium, LLC | $120.19 | 2023-2025 | Azstarys |
| Axsome Therapeutics, INC. | $92.07 | 2025 | Auvelity |
| Tris Pharma INC | $73.46 | 2023-2025 | Dyanavel Xr |
| E.R. Squibb & Sons, L.L.C. | $53.99 | 2025 | Cobenfy |
| Almatica Pharma LLC | $50.11 | 2025 | Loreev Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $42.30 | 2023-2025 | Trintellix |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $30.57 | 2023 | Quviviq |
| Aucta Pharmaceuticals, INC. | $28.96 | 2025 | Motpoly Xr |
| Merck Sharp & Dohme LLC | $14.39 | 2023 | Belsomra |
| Lilly USA, LLC | $13.60 | 2023 | Mounjaro |
| Mylan Specialty L.P. | $12.94 | 2023 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Derrick Bieller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.